Shire is set to approve a $64.3bn by Takeda

By Catherine Sturman
Worth over $30bn, Takeda is not willing to give up on its proposed takeover of pharmaceutical company Shire. The company has had previous bids rejected...

Worth over $30bn, Takeda is not willing to give up on its proposed takeover of pharmaceutical company Shire. The company has had previous bids rejected by the company, yet Shire’s Board has approved a $64.3bn acquisition. At completion, Shire shareholders would own approximately 50%.

The company’s new bid has is fourth offer placed on the table. Takeda is continuing to expand its international reach but faces increased challenges in the pricing of drugs amongst growing competition in a number of rare diseases.

The deal will enable Takeda to further its presence within the US. If successful, it will become one of the largest international acquisitions this year, and could compete with international giants, such as AstraZeneca, The Telegraph reports.

See also

However, Takeda shares have dipped by close to 10% upon the news release, highlighting the unease of shareholders. Shire is presently twice the size of Takeda, so it is unknown how such a takeover will impact the business.

"While this offer represents a solid improvement over Takeda's third bid (38% cash), we still wonder if it is enough to satisfy Shire shareholders," Jefferies analyst David Steinberg informed CNBC.

Nonetheless, Shire’s board has agreed on an extension to the previous regulatory deadline, and now have up to May 8th to make a final decision.

Share

Featured Articles

Hyfe AI uses acoustic AI in its digital cough monitoring

Hyfe uses acoustic AI in its digital cough monitoring. Dr. Joe Brew, Co-Founder & CEO of Hyfe AI, tells us more about coughing technology post-COVID-19

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Digital Healthcare

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma